An Update On Surface Pharmaceuticals

May 15, 2018
Investment will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates
Read full article >>

October 24, 2017
Experienced Team to Advance Ocular Surface Disease Care by Seeking FDA-Approval for Three Branded Drug Programs Through FDA’s 505(b)(2) Development Pathway
Read full article >>